display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)mHCC - 1st line (L1)
Immune checkpoint association
durvalumab plus tremelimumab HIMALAYA
nivolumab plus ipilimumab NCI-2018-01106
nivolumab plus ipilimumab plus SoC CheckMate 9DW

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons